A randomized, double-blind, placebo-controlled trial of lenalidomide in the treatment of moderately severe active Crohn's disease

J C Mansfield, M Parkes, A B Hawthorne, A Forbes, C S J Probert, R C Perowne, A Cooper, J B Zeldis, D C Manning, C J Hawkey

Research output: Contribution to journalArticlepeer-review

32 Citations (Scopus)


Therapy targeted at tumour necrosis factor-alpha has an established role in Crohn's disease. Lenalidomide, an analogue of thalidomide, is an oral immunomodulatory agent with powerful antitumour necrosis factor-alpha properties. It is licensed for myeloma and myelodysplastic syndrome. Based upon reports of thalidomide efficacy, lenalidomide was evaluated in Crohn's disease.
Original languageEnglish
Pages (from-to)421-430
Number of pages10
JournalAlimentary Pharmacology and Therapeutics
Issue number3
Publication statusPublished - 1 Aug 2007


  • Adolescent
  • Adult
  • Aged
  • Crohn Disease
  • Double-Blind Method
  • Female
  • Humans
  • Immunosuppressive Agents
  • Male
  • Middle Aged
  • Placebos
  • Severity of Illness Index
  • Thalidomide
  • Treatment Outcome
  • Venous Thrombosis

Cite this